[
  {
    "ts": "2025-11-15T04:50:53+00:00",
    "headline": "Gilead Sciences, Inc. (GILD)’s Mixed Quarter Draws Divergent Analyst Views",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best blue-chip stocks to buy now. On November 3, Bernstein SocGen Group reiterated its “Outperform” rating on Gilead Sciences, Inc. (NASDAQ: GILD), setting a price target of $135. The firm highlighted the company’s solid third-quarter performance and noted continued strength in HIV therapies and emerging treatments as […]",
    "url": "https://finance.yahoo.com/news/gilead-sciences-inc-gild-mixed-045053894.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "1762b7ea-04db-31cc-b67f-a321564aca26",
      "content": {
        "id": "1762b7ea-04db-31cc-b67f-a321564aca26",
        "contentType": "STORY",
        "title": "Gilead Sciences, Inc. (GILD)’s Mixed Quarter Draws Divergent Analyst Views",
        "description": "",
        "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best blue-chip stocks to buy now. On November 3, Bernstein SocGen Group reiterated its “Outperform” rating on Gilead Sciences, Inc. (NASDAQ: GILD), setting a price target of $135. The firm highlighted the company’s solid third-quarter performance and noted continued strength in HIV therapies and emerging treatments as […]",
        "pubDate": "2025-11-15T04:50:53Z",
        "displayTime": "2025-11-15T04:50:53Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/b289a344cf46bb20faecd01ed5dc6107",
          "originalWidth": 240,
          "originalHeight": 160,
          "caption": "Gilead Sciences, Inc. (GILD)’s Mixed Quarter Draws Divergent Analyst Views",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mRO6Vt56QsZVpg163jv5EQ--~B/aD0xNjA7dz0yNDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/b289a344cf46bb20faecd01ed5dc6107.cf.webp",
              "width": 240,
              "height": 160,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zAmBXhGzahEZsMNHkCwDog--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/b289a344cf46bb20faecd01ed5dc6107.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-inc-gild-mixed-045053894.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-inc-gild-mixed-045053894.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]